IN THE SPECIFICATION

On page 1, after the title, please add the following sentence:

"This application is a 371 of PCT/CA00/00770 filed 6/30/2000"

On page 4, please replace par. 1 with the following amended paragraph:

Trans-ACPD has also been shown to be a neuroprotective agent in a medial cerebral artery occlusion (MCAO) model in mice (Chiamulera *et al. Eur. J. Pharmacol.* ~~215~~216, ~~353~~335, 1992), and it has been shown to inhibit NMDA-induced neurotoxicity in nerve cell cultures (Koh v, *Proc. Natl. Acad. Sci. USA* 88, 9431, 1991). The mGluR-active compounds are also implicated in the treatment of pain. This is proved by the fact that antagonists at the mGluRs antagonize sensory synaptic response to noxious stimuli of thalamic neurons (Eaton, S. A. *et al.*, *Eur. J. Neuroscience*, 5, 186, 1993).

On page 14, please replace par. 1 with the following amended paragraph:

R1, R2, R3, R4, R5 and R6 are as defined above, R8 and R9 ~~are~~ each independently represent a hydrogen atom, a (C_2-C_6) alkanoyl group, a (C_1-C_4) alkyl group, a (C_3-C_4) alkenyl group or a phenyl (C_1-C_4) alkyl group, wherein the phenyl is unsubstituted or substituted by halogen, (C_1-C_4) alkyl or (C_1-C_4) alkoxy, or a salt thereof; or

On page 19, please replace par. 2 with the following amended paragraph:

Compounds of formulae (VII), ~~(VII)~~ (VIII), (IX) and (X) are either commercially available or may be prepared using standard procedures known to a person skilled in the art. Compounds of formulae (VII), ~~(VII)~~ (VIII), (IX) and (X), wherein at least one of R3, R4, R5 and R6 is other than H may be prepared from the compounds of formulae (VII), ~~(VII)~~ (VIII), (IX) and (X) respectively, wherein R3, R4, R5 and R6 is H, via standard reactions known to a person skilled in the art. For example: electrophilic substitution with appropriate electrophile, Friedel-Crafts alkylation or acylation, followed by further manipulations of the formed products within the knowledge of a worker skilled in the art.

On page 25, please replace par. 4 with the following amended paragraph:

~~In~~ Ex *vivo* testing for demonstration of the pharmacological activity of certain compounds on representative mGlu receptor subtypes can be performed using Sprague Dawley rat tissue.

On page 32, please replace par. 3 with the following amended paragraph:

The above ingredients are mixed ~~a nd~~ and filled into hard giant gelatin capsules in 460 mg quantities.

On page 38, please replace par. 3 with the following amended paragraph:

The ~~follwing~~ following abbreviations are used in the Examples: EtOAC, ethyl acetate; THF, tetrahydrofuran; EtOH, ethanol; TLC, thin layer chromatography; GC' gas chromatography; HPLC, high pressure liquid chromatography; Et_2O, diethyl ether; DMSO, dimethyl sulfoxide; DBU, 1,8-diazabicyclo-[5.4.0]undec-7-ene.

On page 43, please par. 1 with the following amended paragraph:

Trimethylsilyl iodide was added to a stirred solution of compound (11) in pyridine (0.429 mL) and $CHCl_3$ (292 mL) under inert atmosphere. The resulting mixture was stirred for 1.5 h, followed by a further addition of 0.3 mL of trimrthylsilyl iodide. The mixture was stirred for additional 40 min and then quenched with 80 mL of ice cold $NaHCO_3$ solution and stirred for 10 min and then poured into brine and extracted with ethyl acetate (2 x 200 mL). The ~~resultion~~resulting solution was washed with brine, dried over $MgSO_4$ and evaporated to obtain crude compound (12) as a gum. The crude product was purified by column chromatography (hexanes: EtOAc 8:1-85:15) to yield 1.9 g (65.3%) of compound (12).